Overview
Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors
Status:
Completed
Completed
Trial end date:
2016-11-11
2016-11-11
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to assess the safety and tolerability of BMS-663513 in subjects with advanced and/or metastatic malignant tumors.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Bristol-Myers SquibbCollaborator:
Ono Pharmaceutical Co. LtdTreatments:
Nivolumab
Criteria
For more information regarding BMS clinical trial participation, please visitwww.BMSStudyConnect.com
Inclusion Criteria:
- Subjects with previously treated advanced malignant solid tumor
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
- For certain subjects, willing and able to provide pre-treatment tumor sample
Exclusion Criteria:
- Known or suspected central nervous system metastases or central nervous system as the
only source of disease
- Other concomitant malignancies (with some exceptions per protocol)
- Active, known or suspected autoimmune disease